160
Participants
Start Date
January 20, 2021
Primary Completion Date
September 30, 2039
Study Completion Date
September 30, 2039
CTX001
CTX001 infusion.
Columbia University Medical Center (21+ years), New York
Columbia University Medical Center, New York
Children's Hospital of Philadelphia, Philadelphia
Atrium Health Levine Children's Hospital, Charlotte
The Children's Hospital at TriStar Centennial Medical Center/ Sarah Cannon Center for Blood Cancers, Nashville
St. Jude Children's Research Hospital, Memphis
Ann & Robert Lurie Children's Hospital of Chicago, Chicago
Methodist Healthcare System of San Antonio, Methodist Hospital, Methodist Children's Hospital, San Antonio
Lucile Packard Children's Hospital, Palo Alto
Hopital Universitaire des Enfants Reine Fabiola (HUDERF), Brussels
The Hospital for Sick Children, Toronto
Toronto General Hospital, University Health Network, Toronto
St. Paul's Hospital, Vancouver
University Hospital Duesseldorf - Department of Pediatric Oncology, Hematology and Clinical Immunology, Düsseldorf
Regensburg University Hospital, Clinic and Polyclinic for Paediatric and Adolescent Medicine, Regensburg
University Hospital Tuebingen, Tübingen
Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica Ospedale Pediatrico Bambino Gesu - IRCCS, Rome
Imperial College Healthcare NHS Trust, Hammersmith Hospital, London
University College London Hospitals NHS Foundation Trust, London
Collaborators (1)
CRISPR Therapeutics
INDUSTRY
Vertex Pharmaceuticals Incorporated
INDUSTRY